2月27日,荣昌生物(688331/09995)发布公告,2024年度主要财务数据为初步核算数据,未经审计。报告期内,公司实现营业总收入17.15亿元,同比增加58.4%。然而,归母净利润约亏损14.68亿元,归母净利润扣除非经常性损益后约亏损15亿元。报告期末,公司总资产为54.99亿元,较期初减少0.53%;归母所有者权益为19.86亿元,较期初减少42.21%。此次亏损主要是由于新药研发投入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.